← Shenyang Xingqi Pharmaceutical overview

Shenyang Xingqi Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shenyang Xingqi Pharmaceutical Co Ltd (300573.CS)

Q3 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

August 202628 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Latest28 Jul – 11 Sep 2026

▲3

Xingqi's profit jumps, buyback done, pipeline advances despite new rival

First-half profit and dividend beat expectations Xingqi's first-half net profit rose 28.5% to 430 million yuan on 20.5% higher revenue, with an 82% gross margin. It will pay a cash dividend of 3 yuan per 10 shares, about 106 million yuan. Strong earnings and cash return support the stock price.
The interim results and dividend are the core new financial news that directly lift investor confidence and the stock's value.
Company completed 100 million yuan buyback in a week Xingqi finished its 80-100 million yuan share buyback plan in about a week, paying the full 100 million yuan by August 4. Buying back its own stock reduces shares outstanding and signals management's confidence, which tends to support the price.
The buyback is a concrete capital action that shows management's belief in the company and can lift the share price.
New eye-drop drug gets clinical trial approval Xingqi received NMPA approval to start clinical trials for SQ-23082 eye drops, a Class 2.1 modified new drug for allergic conjunctivitis itching. No similar product is sold in China or abroad, so success could open a new market and add future revenue.
This pipeline advance is new technology news that could expand Xingqi's product line and long-term growth.
Qilu's atropine application accepted, but Xingqi still leads Qilu Pharmaceutical's application for atropine sulfate eye drops was accepted, adding a potential rival in children's myopia. However, Xingqi remains the only approved product, with 2025 sales up 212% to 603.6 million yuan. Qilu's launch timing is uncertain, so the near-term threat is limited.
This is the main competitive development that could pressure future pricing, but Xingqi's first-mover advantage currently outweighs it.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.